Fractyl Health (GUTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Apr, 2026Executive summary
The annual meeting is scheduled for June 10, 2026, at 12:00 p.m. ET, conducted virtually to increase participation and reduce costs.
Record date for voting is April 17, 2026, with 158,648,963 shares outstanding and entitled to vote.
Stockholders can vote by internet, phone, mail, or during the virtual meeting using a 16-digit control number.
Two main proposals are up for vote: election of three Class II directors and ratification of EY as independent auditor.
Voting matters and shareholder proposals
Proposal 1: Elect Marc Elia, Clive Meanwell, and Ian Sheffield as Class II directors for three-year terms ending 2029.
Proposal 2: Ratify appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026.
Board recommends voting FOR all director nominees and FOR auditor ratification.
Only business described in the proxy or properly brought before the meeting will be considered.
Board of directors and corporate governance
Board consists of nine members divided into three classes, with annual staggered elections.
Eight of nine directors are independent, including the Chairman and all committee members.
Board committees: Audit, Compensation and Human Strategy, Nominating and Corporate Governance.
Regular self-evaluations, robust stockholder engagement, and no poison pill in place.
Insider trading and anti-hedging policies prohibit hedging and pledging of company securities.
Latest events from Fractyl Health
- Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.GUTS
Proxy filing - Revita nears pivotal data for post-GLP-1 weight maintenance as Rejuva enters clinical trials.GUTS
Canaccord Genuity's 46th Annual Growth Conference - Revita maintained up to 84% of GLP-1 weight loss; net loss narrowed, but liquidity risks persist.GUTS
Q2 2026 - Revita enabled up to 84% weight loss retention at one year post-GLP-1, with strong safety data.GUTS
Study result - Innovative device and gene therapy programs target durable weight maintenance in obesity and diabetes.GUTS
Chardan's 8th Annual Genetic Medicines Conference - Director elections and auditor ratification approved; no questions raised by stockholders.GUTS
AGM 2026 - Revita targets durable weight maintenance post-GLP-1, with pivotal data and filing expected in 2024.GUTS
Bank of America Global Healthcare Conference 2026 - Q1 2026 net income turned positive on non-cash gains; cash runway into early 2027.GUTS
Q1 2026 - Virtual annual meeting to elect directors and ratify auditor, with online voting available.GUTS
Proxy filing